FIGO @entity1204 : resection of macroscopic XXXX and other determinants of survival.

@entity1 @entity3018 @entity66 @entity1204
The objective of this study was to evaluate the potential survival benefit of debulking macroscopic @entity3018 and other clinical prognostic factors among @entity1 with node-positive @entity1204 . Demographic, operative, pathologic, and follow-up data were abstracted retrospectively for 41 eligible @entity1 with FIGO stage IIIC @entity1204 . Survival curves were generated using the Kaplan-Meier method and statistical comparisons were performed using the log rank test, logistic regression analysis, and the Cox proportional hazards regression model. All @entity1 had positive pelvic lymph nodes and 20 @entity1 (48.8%) had positive para-aortic lymph nodes. Postoperatively, all @entity1 received whole pelvic radiation therapy, 17 received extended-field radiation therapy, and 15 @entity1 received chemotherapy. The median @entity66 ( @entity66 ) time for all @entity1 was 30.6 months (median follow-up 34. 0 months). @entity1 with completely resected macroscopic lymphadenopathy had a significantly longer median @entity66 time (37.5 months), compared to @entity1 left with gross residual @entity66 (8.8 months, P = 0.006). On multivariate analysis, independent predictors of @entity66 were gross residual @entity66 (HR 7.96, 95% CI 2.54-24.97, P < 0. 001), age > or = 65 years (HR 6.22, 95% CI 2.05-18.87, P = 0.001), and the administration of adjuvant chemotherapy (HR 0.22, 95% CI 0.07-0.76, P = 0.016). We conclude that in @entity1 with @entity1204 , complete resection of macroscopic @entity66 and the administration of adjuvant chemotherapy, in addition to directed radiation therapy, are associated with improved survival.
